SKLB-163
CAS No. 1255099-06-9
SKLB-163( SKLB 163 | SKLB163 )
Catalog No. M27829 CAS No. 1255099-06-9
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 302 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | 1368 | Get Quote |
|
| 500MG | 2673 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSKLB-163
-
NoteResearch use only, not for human use.
-
Brief DescriptionSKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
-
DescriptionSKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
-
In Vitro——
-
In Vivo——
-
SynonymsSKLB 163 | SKLB163
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorGABAA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1255099-06-9
-
Formula Weight405.92
-
Molecular FormulaC18H16ClN3O2S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClCC(=O)Nc1ccc2nc(SCC(=O)NCc3ccccc3)sc2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Divya K Nair, et al. Synthesis of imidazopyridines from the Morita-Baylis-Hillman acetates of nitroalkenes and convenient access to Alpidem and Zolpidem. Org Lett. 2012 Sep 7;14(17):4580-3.
molnova catalog
related products
-
R1487
R1487 is an orally bioavailable and highly selective p38α mitogen-activated protein kinase inhibitor.
-
Antimicrobial agent-...
Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment of cataracts, ulcerative colitis, meningitis and Kawasaki's disease and Parkinson's disease.
-
Losmapimod
Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
Cart
sales@molnova.com